GS-9667

GS-9667 (CVT 3619), a novel N6-5'-substituted adenosine analog, is a selective, partial agonist of the A1 adenosine receptor (A1AdoR) . GS-9667 binds to adipocyte membranes with high (KH=14 nM) and low (KL=5.4 μM) affinities. GS-9667 reduces cyclic AMP content and release of nonesterified fatty acids from epididymal adipocytes with IC50 values of 6 nM and 44 nM, respectively. GS-9667 inhibits lipolysis and has the potential for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA) [1][2].

Product Specifications

CAS Number

[618380-90-8]

Product Name Alternative

CVT 3619

UNSPSC

12352005

Target

Adenosine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/gs-9667.html

Purity

98.08

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O[C@H]1[C@@H](O[C@@H]([C@H]1O)CSC2=C(C=CC=C2)F)N3C4=NC=NC(N[C@H]5[C@@H](CCC5)O)=C4N=C3

Molecular Formula

C21H24FN5O4S

Molecular Weight

461.51

References & Citations

[1]Marjan Fatholahi, et al. A novel partial agonist of the A (1) -adenosine receptor and evidence of receptor homogeneity in adipocytes. J Pharmacol Exp Ther. 2006 May;317 (2) :676-84. |[2]Peter M Staehr, et al. Reduction of free fatty acids, safety, and pharmacokinetics of oral GS-9667, an A (1) adenosine receptor partial agonist. J Clin Pharmacol. 2013 Apr;53 (4) :385-92.